Losartan, an angiotensin receptor blocker, has shown similar effects by attenuating myocardial fibrosis and preventing cardiac hypertrophy in non-obstructive hypertrophic cardiomyopathy by suppressing TGF-β and collagen signaling pathways [160]. The gene discussed is TGFB1; the disease is cardiac hypertrophy.